Biotech Startup Cellogen Therapeutics Raises ₹20 Cr from Kotak Alts

by · Inc42

SUMMARY

  • Kotak Alts invested ₹20 Cr in Cellogen Therapeutics, a cell and gene therapy startup developing CAR-T treatments for cancers and blood disorders
  • The investment, made via the Kotak Life Sciences Fund I (KLSF-I), comes after Natco Pharma earlier acquired over 5% stake in Cellogen for ₹15 Cr
  • Cellogen’s next-generation CAR-T therapies aim to be more affordable and effective than existing options in the market, bringing cost down from $500K to $60K